After five years and some 60 deals that have turned Valeant Pharmaceuticals International Inc into a stock market darling with a market capitalization of $22 billion, Chief Executive Michael Pearson still has some surprises up his sleeve.One was the Canadian drugmaker's pursuit of U.S.-based generic pharmaceutical company Actavis Inc, a prize worth more than $13 billion that would be both Valeant's biggest deal by far and a move into less familiar territory.The deal stalled after the companies failed to agree on terms, people familiar with the situation said. An Actavis spokesman failed to comment and Valeant did not respond to inquiries. It was not clear if the deal could be revived.
Actavis Inc., formerly Watson Pharmaceuticals, Inc. Shares of ACT fell by 0.33% or $-0.345/share to $105.24. In the past year, the shares have traded as low as $67.67 and as high as $107.76. On average, 1148380 shares of ACT exchange hands on a given day and today's volume is recorded at 1533388.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 0.3% or $0.23/share to $76.17. In the past year, the shares have traded as low as $42.47 and as high as $76.57. On average, 1367630 shares of VRX exchange hands on a given day and today's volume is recorded at 1027498.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX fell by 0.13% or $-0.1/share to $76.73. In the past year, the shares have traded as low as $43.99 and as high as $77.70. On average, 418571 shares of VRX.TO exchange hands on a given day and today's volume is recorded at 291241.
Source
